Engility Holdings (EGL) Soars: Stock Adds 10.5% in Session

In this article:

Engility Holdings, Inc. EGL was a big mover last session, as the company saw its shares rise more than 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 19% in the past one-month time frame.

The upside was likely driven by reports that the company may be exploring a potential sale to other peer defense contractors.

The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Engility Holdings currently has a Zacks Rank #2 (Buy) while its Earnings ESP is negative.  

Engility Holdings, Inc. Price

Engility Holdings, Inc. Price | Engility Holdings, Inc. Quote

Investors interested in the Aerospace - Defense industry may consider Northrop Grumman Corporation NOC, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is EGL going up? Or down? Predict to see what others think:Up or Down

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>
 


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Northrop Grumman Corporation (NOC) : Free Stock Analysis Report
 
Engility Holdings, Inc. (EGL) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Advertisement